CYT-1010
Moderate to Severe Pain (e.g., Post-Surgical Pain)
Phase 2Active
Key Facts
Indication
Moderate to Severe Pain (e.g., Post-Surgical Pain)
Phase
Phase 2
Status
Active
Company
About Cytogel Pharma
Cytogel Pharma is a private, clinical-stage biotech company pioneering a new class of pain therapeutics based on the endomorphin peptide family. Its lead candidate, CYT-1010, has completed Phase 1 trials demonstrating safety and analgesic activity and is advancing into Phase 2. The company's core value proposition is developing potent, non-addictive analgesics that could transform the treatment of moderate to severe pain, addressing a critical unmet need in the midst of the opioid crisis.
View full company profile